91 related articles for article (PubMed ID: 25098308)
1. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer.
Xi Y; Guo R; Hu J; Zhang M; Zhang X; Li B
Nucl Med Commun; 2014 Nov; 35(11):1112-8. PubMed ID: 25098308
[TBL] [Abstract][Full Text] [Related]
2. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
3. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
Higashi T; Saga T; Nakamoto Y; Ishimori T; Mamede MH; Wada M; Doi R; Hosotani R; Imamura M; Konishi J
J Nucl Med; 2002 Feb; 43(2):173-80. PubMed ID: 11850481
[TBL] [Abstract][Full Text] [Related]
4. Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography correlate with prognostic parameters in breast cancer.
Chang CC; Tu HP; Chen YW; Lin CY; Hou MF
J Int Med Res; 2014 Dec; 42(6):1209-21. PubMed ID: 25339454
[TBL] [Abstract][Full Text] [Related]
5. Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?
Santhosh S; Mittal BR; Bhasin D; Rana SS; Bhattacharya A; Srinivasan R; Nada R; Gupta R
Nucl Med Commun; 2014 Oct; 35(10):1018-25. PubMed ID: 25023999
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
7. Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers of breast cancer.
Kaida H; Azuma K; Toh U; Kawahara A; Sadashima E; Hattori S; Akiba J; Tahara N; Rominger A; Ishii K; Murakami T; Ishibashi M
Hell J Nucl Med; 2018; 21(1):35-42. PubMed ID: 29550845
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Preoperative assessment of malignant potential of gastrointestinal stromal tumor by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging: Usefulness of standardized uptake value and retention index.
Kwon Y; Park E; Pahk K; Kim S; Kim MJ; Graf D; Park S
J Cancer Res Ther; 2019; 15(1):142-147. PubMed ID: 30880770
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
[TBL] [Abstract][Full Text] [Related]
11. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
12. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET.
Lee SM; Kim TS; Lee JW; Kim SK; Park SJ; Han SS
Clin Nucl Med; 2011 May; 36(5):331-6. PubMed ID: 21467846
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Role of Dual-Time-Point (18)F-FDG PET/CT in Differential Diagnosis of the Thyroid Incidentaloma.
Lee S; Park T; Park S; Pahk K; Rhee S; Cho J; Jeong E; Kim S; Choe JG
Nucl Med Mol Imaging; 2014 Jun; 48(2):121-9. PubMed ID: 24900152
[TBL] [Abstract][Full Text] [Related]
14. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer.
Ahn SJ; Park MS; Lee JD; Kang WJ
Ann Nucl Med; 2014 Jun; 28(5):430-5. PubMed ID: 24623151
[TBL] [Abstract][Full Text] [Related]
15. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT.
Epelbaum R; Frenkel A; Haddad R; Sikorski N; Strauss LG; Israel O; Dimitrakopoulou-Strauss A
J Nucl Med; 2013 Jan; 54(1):12-8. PubMed ID: 23166388
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
[TBL] [Abstract][Full Text] [Related]
17. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
18. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cell proliferation in renal cell carcinoma using dual-phase
Onishi R; Noguchi M; Kaida H; Moriya F; Chikui K; Kurata S; Kawahara A; Kage M; Ishibashi M; Matsuoka K
Oncol Lett; 2015 Aug; 10(2):822-828. PubMed ID: 26622577
[TBL] [Abstract][Full Text] [Related]
20. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
